Last updated: May 24, 2026
Executive summary: Acitretin sourcing is dominated by European and Indian generic API makers and toll manufacturers that supply acitretin (and related retinoid intermediates) to branded and generic dermatology players. In practice, “suppliers” splits into (1) acitretin API manufacturers, (2) formulation and fill-finish CDMOs producing acitretin capsules, and (3) intermediate suppliers for retinoid chemistry. Without a specific target geography, dossier type, or brand/capsule strength, a complete, defensible supplier list cannot be produced from authoritative, citable sources.
Which companies supply acitretin (API) for generic dermatology products?
Direct answer: There is no single, globally consistent supplier set for acitretin API. The market is served by multiple manufacturers whose availability and compliance status vary by region, inspection outcomes, and customer qualification cycles.
What does “acitretin supplier” typically mean in procurement?
Procurement teams usually map to three vendor classes:
- Acitretin API manufacturers (small molecule API).
- Intermediate manufacturers for retinoid synthesis (often more numerous than finished API suppliers).
- Formulation and packaging CDMOs for acitretin capsules (including gel-filled and soft/hard capsule filling, depending on dosage form and local practice).
How to screen acitretin API suppliers (quality and compliance)
For acitretin, qualification typically requires:
- GMP manufacturing for API
- CoA and impurity profile control
- Consistency of particle size, polymorph/metastable form where applicable
- Regulatory support packages for DMF/ASMF or customer dossier cross-references
Which CDMOs formulate and fill acitretin capsules?
Direct answer: A number of CDMOs support capsule manufacturing for small-molecule dermatology products, but a specific acitretin capsule supplier list depends on strength, capsule type, and whether the product is a generic or branded tender.
Dosage form constraints that affect CDMO eligibility
- Capsule fill and excipient set compatibility
- Light/oxygen sensitivity handling typical for retinoids
- Stability data required for NDA/ANDA support packages
Who supplies acitretin intermediates used in retinoid synthesis?
Direct answer: Intermediate suppliers often outnumber direct acitretin API suppliers, but procurement relevance is driven by customers’ preferred synthetic route and regulatory documentation strategy.
Intermediate categories procurement teams track
- Retinoid-building blocks used to assemble the polyene/functionalized skeleton
- Key chiral or protected intermediates, where route requires it
- Solvents and reagents for polyene coupling steps
How does acitretin API sourcing differ by region (US, EU, India, China)?
Direct answer: Sourcing patterns vary by inspection history and dossier alignment more than by technical feasibility. US-EU portfolios often prefer vendors with established regulatory dossiers (DMF/ASMF) and a track record of successful FDA or EMA inspections.
US-oriented sourcing pattern
- Higher fraction of suppliers that support US regulatory documentation
- Tighter impurity control and detailed batch release packages
EU-oriented sourcing pattern
- Preference for vendors already supplying to EU MAHs with validated QMS
- Continued emphasis on compliance and deviation reporting performance
What are the common commercial risks when sourcing acitretin?
Direct answer: The main risks are supply continuity, impurity drift across batches, and lead-time volatility driven by retinoid-chemistry route complexity.
Quality risks that trigger qualification delays
- Impurity profile changes from raw material source shifts
- Rework or reprocessing due to polyene-related sensitivity
- Stability or packaging compatibility issues for capsule products
Supply risks
- Tight production windows for specialized intermediates
- Capacity constraints during regulatory batch campaigns
How many acitretin API suppliers realistically exist?
Direct answer: In practice, the usable supplier count for qualified, dossier-ready customers is smaller than the number of manufacturers that could technically produce acitretin. Qualification filters (GMP history, dossier support, inspection readiness, and customer experience) reduce the pool.
Key Takeaways
- “Acitretin suppliers” should be segmented into API makers, intermediate suppliers, and capsule CDMOs.
- Regional sourcing depends on regulatory documentation alignment and inspection outcomes, not only chemistry capability.
- Qualification bottlenecks are usually impurity control consistency and retinoid stability/handling requirements.
- A complete supplier list requires brand-strength and geography to map to qualified, regulatory-ready vendors.
FAQs
- What supplier requirements apply to acitretin API for ANDA submissions?
- Which excipients and capsule types are most commonly used in acitretin capsule manufacturing?
- How do customers qualify acitretin suppliers for impurity profile consistency across batches?
- What lead-time and capacity constraints affect acitretin API and retinoid intermediates?
- What regulatory documentation supports acitretin API sourcing in the US and EU (DMF/ASMF, CoA packages)?
References
No citable supplier sources were provided or retrievable within the supplied information to support an accurate, named-company supplier list for acitretin.
